Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
2023-06-13
免疫疗法疫苗临床研究临床2期临床结果
OXFORD, UK I June 12, 2023 I Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of
autoimmunity
, chronic infectious diseases
and cancer
, today announced the dosing of the first patient in the PCA001 clinical trial (NCT05617040). PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA)
response, and T cell response of VTP-850 monotherapy in men with rising PSA
after definitive local therapy for their disease (i.e., biochemical recurrence).VTP-850 is a next-generation
prostate cancer
immunotherapeutic candidate which utilizes Vaccitech’s sequential dosing approach of two proprietary nonreplicating viral vectors, ChAdOx and MVA. PCA001 builds on the previous promising data from the University of Oxford VANCE01 (NCT02390063) and ADVANCE (NCT03815942) trials, Phase 1 and Phase 1/2 clinical trials respectively, of VTP-800, the first-generation product candidate which encoded 5T4
, an antigen expressed by most prostate cancers.1,2 VTP-850 is a multi-antigen immunotherapeutic candidate containing four prostate-associated antigens: PSA
, PAP, STEAP1
and 5T4
. The first phase of the trial is enrolling participants in the US, with plans to open further sites in Italy and Spain.“20-40% of patients will unfortunately experience biochemical recurrence following initial local therapy for
prostate cancer
with the potential to experience metastases.3 VTP-850 is our next-generation, multi-antigen product candidate designed to induce a targeted polyclonal T cell response to kill remaining tumor
cells and prevent advancement to metastatic disease,” said Bill Enright, Chief Executive Officer of Vaccitech. “We saw very encouraging data from the VANCE01 and ADVANCE trials, and we are excited to begin PCA001 where VTP-850 will be evaluated as a monotherapy in a patient population with important unmet medical needs.”“VTP-850 encodes four
prostate cancer
antigens and is designed to induce a broader T cell response to tumor
cells,” said Dr. Meg Marshall, Chief Medical Officer of Vaccitech. “When the immune system targets multiple molecules on tumor
cells, it is generally harder for tumor
cells to escape destruction by the immune system.”About
Prostate Cancer
In 2020,
prostate cancer
was the fourth most common cancer
worldwide, with 1.4 million new cases diagnosed.4 In the US, out of every 100 American men, about 13 will get prostate cancer
during their lifetime.5 In the UK, prostate cancer
is the most common cancer
in men, with more than 52,000 people diagnosed with the disease on average each year.6 20-30% of patients experience rising levels of PSA
after local therapy (e.g. prostatectomy), indicating that disease was not cured by local therapy.7 Of men who do experience biochemical recurrence, there is a 1 in 9 chance of developing metastases.8About Vaccitech
Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat and cure
chronic infectious diseases
, autoimmune diseases
, and cancer
. The Company stands apart through a proprietary, multi-platform approach that has shown the ability to induce higher magnitudes of T cells compared with other technologies. Vaccitech is uniquely positioned to address the needs of large, underserved patient populations through a diverse clinical-stage pipeline of investigational therapies targeting diseases that pose significant public health risk and have limited treatment options. The Company’s lead product candidates include VTP-300, an immunotherapy product candidate designed as a component of a potential functional cure for chronic hepatitis B viral (HBV) infection
; VTP-200, a non-invasive, early-stage investigational treatment for persistent, high-risk human papillomavirus (HPV) infection
; VTP-850, a novel T cell investigational therapy for prostate cancer
; and VTP-1000, a preclinical T cell therapeutic candidate designed to restore immune tolerance in celiac disease
. Vaccitech has proven drug development and scientific expertise in the field of immunization, co-inventing a COVID-19 vaccineCOVID-19
vaccine with the University of Oxford, which is now approved and exclusively licensed worldwide to AstraZeneca.For more information, visit www.vaccitech.co.uk.
SOURCE: Vaccitech
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
前列腺癌,自身免疫性疾病,感染
[+5]
靶点
KLK3,5T4,STEAP1
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。